A follow-up study was conducted to determine the magnitude of and factors related to adherence to artemether/lumefantrine (ALu) treatment in rural settings in Tanzania. Children in five villages of Kilosa District treated at health facilities were followed-up at their homes on Day 7 after the first dose of ALu. For those found to be positive using a rapid diagnostic test for malaria and treated with ALu, their caretakers were interviewed on drug administration habits. In addition, capillary blood samples were collected on Day 7 to determine lumefantrine concentrations. The majority of children (392/444; 88.3%) were reported to have received all doses, in time. Non-adherence was due to untimeliness rather than missing doses and was highest f...
Background: Home-management of malaria (HMM) strategy improves early access of anti-malarial medicin...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
As artemether/lumefantrine is now deployed as the first-line treatment for uncomplicated falciparum ...
A follow-up study was conducted to determine the magnitude of and factors related to adherence to ar...
Adherence to multidosing is challenging worldwide. This study assessed the extent of adherence to mu...
Background: Since November 2006, Coartem® (Artemether-Lumefantrine-ALu) replaced Sulphadoxine-Pyrime...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
Prompt access to artemesinin-combination therapy (ACT) is not adequate unless the drug is taken acco...
Abstract Background Controlled clinical trials have shown that a six-dose regimen of artemether-lume...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malaria in 2006. ...
Abstract. Measuring baseline levels of adherence and identifying risk factors for non-adherence are ...
BACKGROUND: The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the most widel...
Abstract Background Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicate...
BACKGROUND: Use of artemisinin-based combination therapy (ACT), such as artemether-lumefantrine (AL)...
Background: Home-management of malaria (HMM) strategy improves early access of anti-malarial medicin...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
As artemether/lumefantrine is now deployed as the first-line treatment for uncomplicated falciparum ...
A follow-up study was conducted to determine the magnitude of and factors related to adherence to ar...
Adherence to multidosing is challenging worldwide. This study assessed the extent of adherence to mu...
Background: Since November 2006, Coartem® (Artemether-Lumefantrine-ALu) replaced Sulphadoxine-Pyrime...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
Prompt access to artemesinin-combination therapy (ACT) is not adequate unless the drug is taken acco...
Abstract Background Controlled clinical trials have shown that a six-dose regimen of artemether-lume...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malaria in 2006. ...
Abstract. Measuring baseline levels of adherence and identifying risk factors for non-adherence are ...
BACKGROUND: The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the most widel...
Abstract Background Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicate...
BACKGROUND: Use of artemisinin-based combination therapy (ACT), such as artemether-lumefantrine (AL)...
Background: Home-management of malaria (HMM) strategy improves early access of anti-malarial medicin...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
As artemether/lumefantrine is now deployed as the first-line treatment for uncomplicated falciparum ...